Aarkstore - Grifols Therapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Grifols Therapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Browse Full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/26310/grifols-therapeutics-inc-pharmaceuticals-healthcare-deals-and-alliances-profile

Published: Dec 2014| No. Of Pages: 163 Pages

PDF: $ 250 | Site Licence : $ 500 | Enterprise Wide Licence: $ 750

Summary

Grifols Therapeutics, Inc. (Grifols) formerly Talecris Biotherapeutics Inc, is a US-based publicly held pharmaceutical company. It engages in development, production, marketing and distribution of therapies for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), primary immune deficiencies (PI), alpha-1 antitrypsin deficiency, bleeding disorders, infectious diseases and severe trauma. The companys product portfolio comprises of gamunex, an immune globulin intravenous used to treat infectious or inflammatory diseases; hypermunes, a hyperimmune globulin therapy used to treat patients with weak immune systems; koate-DVI is an antihemophilic factor used for treatment of persons with hemophilia; plasbumin, a protein produced by the liver used for the treatment of shock and blood loss due to trauma, burns, and surgery; prolastin; and thrombate III for the treatments of lungs and spontaneous clotting, respectively. Its geographic operations are spread across the US, Canada and Europe. The company received orphan drug designation from the US FDA for its aerosolized Alpha1-Proteinase Inhibitor (Human, A1PI), for the treatment of congenital alpha1-antitrypsin (AAT) deficiency. Grifols is headquartered in Research Triangle Park, the US.

In June 2011, The company was acquired by Grifols USA, LLC.

Grifols Therapeutics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and...